Eribulin-A review of preclinical and clinical studies

Umang Swami, Imran Chaudhary, Mohammad H. Ghalib, Sanjay Goel

Research output: Contribution to journalReview articlepeer-review

71 Scopus citations


Eribulin mesylate is a non-taxane, structurally simplified, completely synthetic, halichondrin B derivative with an end poisoning, microtubule inhibitory action. Preclinical studies have demonstrated activity in various cancer cell lines and synergistic action with gemcitabine, epirubicin, trastuzumab, cisplatin, docetaxel and vinorelbine. Eribulin has recently been approved by United States Food and Drug Administration as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has also advanced to phase II trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Combination trials with carboplatin, gemcitabine, pemetrexed, cisplatin, and erlotinib are currently ongoing. Eribulin potentially has a low incidence of peripheral neuropathy. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism, preclinical studies and clinical trials.

Original languageEnglish (US)
Pages (from-to)163-184
Number of pages22
JournalCritical Reviews in Oncology/Hematology
Issue number2
StatePublished - Feb 2012


  • Breast cancer
  • E7389
  • Eribulin
  • Halaven™
  • Halichondrin B
  • Microtubule inhibitor
  • NSC 707389

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Eribulin-A review of preclinical and clinical studies'. Together they form a unique fingerprint.

Cite this